Rhumbline Advisers Glycomimetics Inc Transaction History

Rhumbline Advisers

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$1.21 - $2.08 $1,263 - $2,171	1,044 New	1,044 $1,000
Q2 2021 Aug 05, 2021	SELL	$2.16 - $3.18 $131,176 - $193,121	-60,730 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$2.69 - $4.24 $21,248 - $33,491	7,899 Added 14.95%	60,730 $228,000
Q3 2020 Nov 12, 2020	SELL	$3.07 - $5.0 $18,573 - $30,250	-6,050 Reduced 10.27%	52,831 $162,000
Q2 2020 Aug 13, 2020	BUY	$2.06 - $3.76 $30,242 - $55,200	14,681 Added 33.21%	58,881 $221,000
Q4 2019 Feb 05, 2020	BUY	$4.03 - $6.5 $1,043 - $1,683	259 Added 0.59%	44,200 $234,000
Q3 2019 Oct 23, 2019	SELL	$2.8 - $12.85 $909 - $4,176	-325 Reduced 0.73%	43,941 $189,000
Q2 2019 Aug 14, 2019	BUY	$10.6 - $13.12 $10,048 - $12,437	948 Added 2.19%	44,266 $528,000
Q1 2019 May 01, 2019	SELL	$9.96 - $13.44 $12,370 - $16,692	-1,242 Reduced 2.79%	43,318 $540,000
Q4 2018 Jan 31, 2019	BUY	$8.47 - $14.71 $121,425 - $210,882	14,336 Added 47.43%	44,560 $422,000
Q3 2018 Nov 07, 2018	SELL	$13.7 - $17.12 $24,153 - $30,182	-1,763 Reduced 5.51%	30,224 $435,000
Q2 2018 Aug 06, 2018	BUY	$14.63 - $19.19 $467,969 - $613,830	31,987 New	31,987 $516,000

17.7M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.2M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.